Financial Performance - The company achieved total operating revenue of 542.79 million yuan, representing a year-on-year increase of 19.66% [3] - Research and development expenses amounted to 83.71 million yuan, accounting for 15.42% of total revenue [3] - The net profit attributable to the parent company was 63.29 million yuan, a significant increase of 451.85% year-on-year [3] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 49.67 million yuan, marking a turnaround from loss to profit compared to the previous year [3] Business Development - The company leveraged its innovative therapy advantages to develop new products and expand its product line, leading to stable sales growth [4] - The ultrasound knife business experienced rapid growth in both sales and net profit during the reporting period [4] - The international business continued to grow rapidly, with the subsidiary Implanet achieving operating revenue of 12.47 million euros, a year-on-year increase of 32.62%, particularly strong in the U.S. market with a growth of 49.30% [4] Financial Position - As of the end of the reporting period, total assets were 2,376.83 million yuan, an increase of 3.04% from the beginning of the period [3] - The equity attributable to the parent company was 2,104.89 million yuan, reflecting a 10.10% increase from the beginning of the period [3] Shareholder Equity - The company implemented a capital reserve transfer plan, increasing the share capital by 34.22% during the reporting period [7] - The increase in share capital was due to the transfer of 2 shares for every 10 shares held and the completion of the acquisition of remaining minority shares of the subsidiary [7]

Group 1 - The company reported a total operating revenue of 543 million yuan for the year 2025, representing a year-on-year increase of 19.66% [1] - Research and development expenses amounted to 83.71 million yuan, accounting for 15.42% of total revenue [1] - The net profit attributable to the parent company reached 63.29 million yuan, a significant increase of 451.85% compared to the previous year [1] - The total assets of the company at the end of the reporting period were 2.377 billion yuan, an increase of 3.04% from the beginning of the period [1] - The equity attributable to the parent company was 2.105 billion yuan, reflecting a growth of 10.10% from the start of the year [1] Group 2 - The company is leveraging its innovative therapy advantages to develop new products and expand its product line, which has led to stable sales growth despite the pressures of volume-based procurement [2] - The ultrasound knife business has seen rapid growth in both sales and net profit during 2025 [2] - The international business, particularly through the subsidiary Implanet, achieved revenue of 12.47 million euros, a year-on-year increase of 32.62%, with the U.S. market showing a remarkable growth of 49.30% [2] - However, the international business is still in the early stages of sales promotion and market expansion, resulting in a loss of approximately 26 million yuan impacting the net profit attributable to the parent company [2] Group 3 - The company recognized share-based payment expenses of approximately 8.4 million yuan due to the implementation of an equity incentive plan [3] - Asset impairment losses and credit impairment losses were estimated at around 34 million yuan, affecting the net profit for 2025 [3] - The company's incubated investment in the Spring Breeze Spine Surgery Robot and related intelligent products is still in the registration and approval phase in China, the U.S., and the EU, and has not yet begun sales, contributing to ongoing losses [3]

Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Insights - The company reported a revenue of 391 million yuan for the first three quarters of 2025, representing a year-on-year increase of 17.65%, and a net profit attributable to shareholders of 62 million yuan, up 623.19% [6] - The company's core growth driver, the Shuimu Tianpeng product line, continues to show rapid growth, with a revenue of 115 million yuan in the first three quarters, an increase of 52.21% [7] - The international business, particularly in the U.S. market, has become a significant growth engine, with overseas revenue reaching over 18 million yuan, nearly doubling year-on-year [7] Financial Performance Summary - For the first three quarters of 2025, the company achieved a revenue of 391 million yuan (+17.65%) and a net profit of 62 million yuan (+623.19%) [6] - The third quarter alone saw a revenue of 142 million yuan (+17.44%) and a net profit of 25 million yuan (+268.13%) [6] - The company expects revenues of 599 million yuan, 759 million yuan, and 952 million yuan for 2025, 2026, and 2027 respectively, with year-on-year growth rates of 32.0%, 26.8%, and 25.4% [9] Growth Drivers - The company’s ultrasound bone knife product line is experiencing rapid growth, with over 50% increase in both shipment volume and sales value for the high-margin consumables [7] - The innovative spinal surgery robot and the JAZZ system are expected to create long-term competitive advantages, with the robot entering the "innovation channel" for expedited approval [8] - The U.S. market has become the largest market for the company’s subsidiary Implanet, with a revenue growth of 83.04% year-on-year [7]

Core Viewpoint - The company has reported strong financial performance for the third quarter of 2025, with significant growth in both domestic and international markets, particularly in the U.S. market, indicating a positive outlook for future operations and expansion efforts [6][7][8]. Financial Performance - In Q3 2025, the company achieved a revenue of 141.71 million yuan, representing a year-on-year increase of 17.44% [6]. - The net profit attributable to shareholders reached 25.38 million yuan, up 268.13% year-on-year [6]. - For the first three quarters of 2025, total revenue was 391.47 million yuan, a 17.65% increase, while net profit attributable to shareholders surged by 623.19% to 61.98 million yuan [6]. Business Segments - The domestic business showed stable growth in surgical volumes and sales performance, while international operations, especially in the U.S., continued to grow significantly [6][7]. - The company’s subsidiary, Waterwood Tianpeng, reported a revenue of 114.92 million yuan for the first three quarters, marking a 52.21% increase, with net profit rising by 179.65% [7]. Product Development - The company received regulatory approval for the JAZZ fixed tension band system in China, enhancing its product line and competitive edge in the spinal surgery market [8]. - The company’s innovative spinal surgery robot and related products have also passed the special review process for innovative medical devices, marking a significant milestone in its R&D efforts [8]. Strategic Decisions - The company has decided to waive its preferential subscription rights for a capital increase in its subsidiary, Implanet, which will reduce its ownership stake from 74.18% to between 63.72% and 64.91% [24][25]. - This decision aligns with the company's strategic planning and funding needs, allowing Implanet to raise capital for market expansion without adversely affecting the company's consolidated financial results [25][40].